• Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=25645078).
  

PubMed=20689758; DOI=10.1593/neo.10414
Tap W.D., Gong K.-W., Dering J., Tseng Y., Ginther C., Pauletti G., Glaspy J.A., Essner R., Bollag G., Hirth P., Zhang C., Slamon D.J.
Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Neoplasia 12:637-649(2010)

PubMed=22515704; DOI=10.1186/1476-4598-11-22
von Euw E.M., Atefi M., Attar N., Chu C., Zachariah S., Burgess B.L., Mok S., Ng C., Wong D.J.L., Chmielowski B., Lichter D.I., Koya R.C., McCannel T.A., Izmailova E., Ribas A.
Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines.
Mol. Cancer 11:22.1-22.9(2012)

PubMed=25645078; DOI=10.1186/s12943-015-0293-5
Atefi M., Titz B., Avramis E., Ng C., Wong D.J.L., Lassen A., Cerniglia M., Escuin-Ordinas H., Foulad D., Comin-Anduix B., Graeber T.G., Ribas A.
Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.
Mol. Cancer 14:27.1-27.12(2015)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)